Acute Radiation Syndrome (ARS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Acute Radiation Syndrome (ARS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Acute Radiation Syndrome (ARS) Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Acute radiation Syndrome Pipeline Analysis report covers 28 drugs currently in different phases of development. Acute Radiation Syndrome also known as radiation toxicity or radiation sickness is an acute illness which occurs after irradiation of the entire body or significant partial body by a high dose of penetrating radiation in a very short period of time. It is categorised into three sub syndromes: the hematopoietic, gastrointestinal and neurovascular syndrome. Symptoms of hematopoietic syndrome are anorexia, fever, and malaise. Gastrointestinal Syndrome is characterised by severe diarrhoea, fever, dehydration, and electrolyte imbalance and symptoms of neurovascular syndromes are extreme nervousness; confusion; severe nausea, vomiting, and watery diarrhoea; burning sensations of the skin; convulsions and loss of consciousness.

The report provides Acute Radiation Syndrome treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report BCN Bioscience, Chrysalis BioTherapeutics, Inc, , and Enzychem Lifesciences Corporation among others.


By Company

By Phase

By Molecule Type

By Region

By Route of Administration

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development Introduction Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code Strategic Developments Clinical trials Clinical trial results Patents Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Atox Bio
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. BCN Bioscience
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Bolder Bio Technology, Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Cellerant Therapeutics, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Cellphire
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Chrysalis BioTherapeutics, Inc
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Cleveland Bio Labs 
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Enzychem Lifesciences Corporation
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. FirstString Research, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Gamida Cell
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Humanetics Corporation
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Inflammatory Response Research, Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. MEABCO A/S
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Medesis Pharma SA
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Neumedicines Inc.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Nohla Therapeutics
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Onconova Therapeutics, Inc.
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Original BioMedicals Co., Ltd.
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Partner Therapeutics, Inc.
6.19.1. Introduction

Atox Bio

BCN Bioscience

Bolder Bio Technology, Inc.

Cellerant Therapeutics, Inc.


Chrysalis BioTherapeutics, Inc

Cleveland Bio Labs

Enzychem Lifesciences Corporation

FirstString Research, Inc.

Gamida Cell

Humanetics Corporation

Inflammatory Response Research, Inc.


Medesis Pharma SA

Neumedicines Inc.

Nohla Therapeutics

Onconova Therapeutics, Inc.

Original BioMedicals Co., Ltd.

Partner Therapeutics, Inc.

  • SKU:
  • Publishing Date: 2018-05-15
  • Product Code: 1
  • Availability: In Stock
  • $2,400.00
  • Ex Tax: $2,400.00

Available Options